• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种结合贝叶斯回归和NONMEM群体分析的三步方法:应用于咪达唑仑

A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

作者信息

Maitre P O, Bührer M, Thomson D, Stanski D R

机构信息

Department of Anesthesiology and Intensive Care, University of Bern, Inselspital, Switzerland.

出版信息

J Pharmacokinet Biopharm. 1991 Aug;19(4):377-84. doi: 10.1007/BF01061662.

DOI:10.1007/BF01061662
PMID:1920085
Abstract

NONMEM, the only available supported program for population pharmacokinetic analysis, does not provide the analyst with individual subject parameter estimates. As a result, the relationship between pharmacokinetic parameters and demographic factors such as age, gender, and body weight cannot be sought by plotting demographic factors vs. kinetic parameters. To overcome this problem, we devised a three-step approach. In step 1, an initial NONMEM analysis provides the population pharmacokinetic parameters without taking into account the demographic factors. Step 2 consists of individual bayesian regressions using the measured drug concentrations for each subject and the population pharmacokinetic parameters obtained in step 1. The bayesian parameter estimates of the individual subject can be plotted against the demographic factors of interest. From the scatter plots, it can be seen which are the demographic factors that appear to affect the pharmacokinetic parameters. In step 3, the NONMEM analysis is resumed, and the demographic factors found in step 2 are entered into the NONMEM regression model in a stepwise manner. This method was used to analyze the pharmacokinetics of midazolam in 64 subjects from 714 plasma concentrations and 11 demographic factors. CL (elimination clearance) and V1 were found to be a function of body weight. Age and liver disease were found to decrease CL. Of the 11 demographic factors recorded for each patient, none was found to influence VSS or intercompartmental clearance.

摘要

NONMEM是唯一可用于群体药代动力学分析的受支持程序,但它无法为分析人员提供个体受试者的参数估计值。因此,无法通过绘制人口统计学因素与动力学参数的关系图来探寻药代动力学参数与年龄、性别和体重等人口统计学因素之间的关系。为克服这一问题,我们设计了一种三步法。第一步,进行初始的NONMEM分析,在不考虑人口统计学因素的情况下提供群体药代动力学参数。第二步包括使用每个受试者的实测药物浓度以及第一步中获得的群体药代动力学参数进行个体贝叶斯回归。个体受试者的贝叶斯参数估计值可以与感兴趣的人口统计学因素进行绘制。从散点图中,可以看出哪些人口统计学因素似乎会影响药代动力学参数。第三步,恢复NONMEM分析,并将第二步中发现的人口统计学因素逐步纳入NONMEM回归模型。该方法用于分析64名受试者中咪达唑仑的药代动力学,数据来自714个血浆浓度和11个人口统计学因素。发现清除率(CL)和中央室分布容积(V1)是体重的函数。发现年龄和肝病会降低CL。在为每位患者记录的11个人口统计学因素中,未发现有因素会影响稳态分布容积(VSS)或隔室间清除率。

相似文献

1
A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.一种结合贝叶斯回归和NONMEM群体分析的三步方法:应用于咪达唑仑
J Pharmacokinet Biopharm. 1991 Aug;19(4):377-84. doi: 10.1007/BF01061662.
2
Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.两种群体药代动力学程序NONMEM和P-PHARM用于他克莫司的比较。
Eur J Clin Pharmacol. 2002 Dec;58(9):597-605. doi: 10.1007/s00228-002-0517-7. Epub 2002 Nov 15.
3
Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.危重症患者咪达唑仑的半机制自动诱导模型:群体药代动力学分析
J Clin Pharm Ther. 2016 Aug;41(4):392-8. doi: 10.1111/jcpt.12395. Epub 2016 May 12.
4
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.咪达唑仑在儿科重症监护患者中的群体药代动力学与代谢
Crit Care Med. 2003 Jul;31(7):1952-8. doi: 10.1097/01.ccm.0000084806.15352.da.
5
Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.与NONMEM相比,贝叶斯估计在群体药代动力学数据分析中的评估:在重症监护病房患者中应用于培氟沙星。
J Pharmacokinet Biopharm. 1992 Dec;20(6):653-69. doi: 10.1007/BF01064424.
6
Population pharmacokinetic analysis of meropenem in Japanese adult patients.美罗培南在日本成年患者中的群体药代动力学分析。
J Clin Pharm Ther. 2011 Apr;36(2):230-6. doi: 10.1111/j.1365-2710.2010.01171.x.
7
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
8
Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics.机械通气期间接受咪达唑仑治疗的极早产儿群体药代动力学建模:咪达唑仑新生儿药代动力学
Anesthesiology. 1999 Feb;90(2):451-7. doi: 10.1097/00000542-199902000-00020.
9
Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy.
J Pharm Sci. 1995 Mar;84(3):307-11. doi: 10.1002/jps.2600840309.
10
Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.危重症患者长期持续输注劳拉西泮和咪达唑仑的比较群体药代动力学
Br J Clin Pharmacol. 2004 Feb;57(2):135-45. doi: 10.1046/j.1365-2125.2003.01957.x.

引用本文的文献

1
Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.建立败血症 94 例婴儿万古霉素群体药代动力学模型及其在个体化治疗中的应用。
BMC Pharmacol Toxicol. 2021 May 4;22(1):26. doi: 10.1186/s40360-021-00489-8.
2
Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?比较具有相关协变量的协变量选择方法:使用先验信息还是数据信息,或者两者的混合?
J Pharmacokinet Pharmacodyn. 2020 Oct;47(5):485-492. doi: 10.1007/s10928-020-09700-5. Epub 2020 Jul 13.
3
Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.

本文引用的文献

1
Effect of age, gender, and obesity on midazolam kinetics.年龄、性别和肥胖对咪达唑仑动力学的影响。
Anesthesiology. 1984 Jul;61(1):27-35.
2
Pharmacokinetics of midazolam in patients recovering from cardiac surgery.
Eur J Clin Pharmacol. 1989;37(2):161-6. doi: 10.1007/BF00558225.
3
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.根据常规临床数据估算药代动力学参数的群体特征。
J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79. doi: 10.1007/BF01061728.
群体药代动力学中使用经验贝叶斯估计进行协变量分析的进一步评估:收缩率和似然比检验的认知
AAPS J. 2017 Jan;19(1):264-273. doi: 10.1208/s12248-016-0001-4. Epub 2016 Oct 19.
4
Inter occasion variability in individual optimal design.个体最优设计中的不同场合间变异性。
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):735-50. doi: 10.1007/s10928-015-9449-6. Epub 2015 Oct 1.
5
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.贝伐单抗在遗传性出血性毛细血管扩张症中的剂量-反应关系
MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693.
6
The effect of food on the high clearance drug asenapine after sublingual administration to healthy male volunteers.食物对健康男性志愿者舌下给药后高清除率药物阿立哌唑的影响。 需注意,你原文中的药物名称可能有误,文本中说的是阿立哌唑(Aripiprazole),而不是阿塞那平(Asenapine),我按照纠正后的药物名称翻译,以免造成误解。若有特殊要求,请根据实际情况调整。
Eur J Clin Pharmacol. 2015 Jan;71(1):65-74. doi: 10.1007/s00228-013-1587-4. Epub 2015 Jan 1.
7
Inter-individual variation in midazolam clearance in children.儿童咪达唑仑清除率的个体间差异。
Arch Dis Child. 2015 Jan;100(1):95-100. doi: 10.1136/archdischild-2013-305720. Epub 2014 Oct 3.
8
Comparison of methods for handling missing covariate data.缺失协变量数据处理方法的比较。
AAPS J. 2013 Oct;15(4):1232-41. doi: 10.1208/s12248-013-9526-y.
9
Multiple imputation of missing covariates in NONMEM and evaluation of the method's sensitivity to η-shrinkage.缺失协变量的 NONMEM 多重插补及其对 η 收缩敏感性的评估。
AAPS J. 2013 Oct;15(4):1035-42. doi: 10.1208/s12248-013-9508-0. Epub 2013 Jul 19.
10
Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.使用群体药代动力学/药效学模型定量分析协变量对稳态苯丙香豆素浓度和效应的影响。
Clin Pharmacokinet. 2013 May;52(5):359-71. doi: 10.1007/s40262-013-0043-z.
4
ASA physical status classifications: a study of consistency of ratings.美国麻醉医师协会身体状况分类:评级一致性研究
Anesthesiology. 1978 Oct;49(4):239-43. doi: 10.1097/00000542-197810000-00003.